ZIMMER BIOMET HOLDINGS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $8.2B | $7.7B | $7.4B | $6.9B | $6.8B |
| Operating income | $1.1B | $1.3B | $1.3B | $696.3M | $860.3M |
| Cost of revenue | $2.5B | $2.2B | $2.1B | $2.0B | $2.0B |
| Cash from operations | $1.7B | $1.5B | $1.6B | $1.4B | $1.5B |
| Capital expenditure | $224.5M | $203.8M | $291.1M | $187.9M | $143.6M |
| Free cash flow | $1.5B | $1.3B | $1.3B | $1.2B | $1.4B |
| Share repurchases | $487.0M | $868.0M | $692.2M | $126.4M | — |
| Impairments | $0 | $0 | $0 | $289.8M | $0 |
| Total assets | $23.1B | $21.4B | $21.5B | $21.1B | $23.5B |
| Total liabilities | $10.4B | $8.9B | $9.0B | $9.0B | $10.8B |
| Total debt | — | — | $5.8B | $5.7B | $7.1B |
Shares outstanding 193.5M · Free float 68.9%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.
Recent filings
- June 29, 2026 8-K
- May 27, 2026 8-K
- May 12, 2026 8-K
- May 1, 2026 10-Q
- April 28, 2026 8-K
- April 28, 2026 8-K
- February 20, 2026 10-K
- February 10, 2026 8-K